Prelude Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $884K | Sell |
14,578
-3,141
| -18% | -$183K | 0.07% | 336 |
|
|
2025
Q4 | $956K | Sell |
17,719
-5,556
| -24% | -$267K | 0.07% | 327 |
|
|
2025
Q3 | $1.05M | Buy |
+23,275
| New | +$1.09M | 0.08% | 299 |
|
|
2025
Q2 | – | Sell |
-9,251
| Closed | -$564K | – | 1026 |
|
|
2025
Q1 | $564K | Sell |
9,251
-16,721
| -64% | -$975K | 0.04% | 467 |
|
|
2024
Q4 | $1.47M | Sell |
25,972
-19,823
| -43% | -$1.11M | 0.09% | 264 |
|
|
2024
Q3 | $2.37M | Buy |
+45,795
| New | +$2.15M | 0.14% | 185 |
|
|
2022
Q4 | – | Sell |
-15,013
| Closed | -$1.13M | – | 1345 |
|
|
2022
Q3 | $1.07M | Buy |
15,013
+11,422
| +318% | +$829K | 0.04% | 402 |
|
|
2022
Q2 | $277K | Buy |
+3,591
| New | +$273K | 0.01% | 1110 |
|
|
2022
Q1 | – | Sell |
-9,455
| Closed | -$635K | – | 1846 |
|
|
2021
Q4 | $590K | Buy |
+9,455
| New | +$555K | 0.02% | 911 |
|
|
2021
Q3 | – | Sell |
-14,034
| Closed | -$924K | – | 1760 |
|
|
2021
Q2 | $938K | Sell |
14,034
-29,332
| -68% | -$1.91M | 0.03% | 645 |
|
|
2021
Q1 | $2.75M | Buy |
+43,366
| New | +$2.7M | 0.07% | 241 |
|
|
2020
Q4 | – | Sell |
-23,771
| Closed | -$1.46M | – | 1328 |
|
|
2020
Q3 | $1.43M | Buy |
+23,771
| New | +$1.43M | 0.07% | 211 |
|
|
2020
Q1 | – | Sell |
-19,088
| Closed | -$1.17M | – | 1464 |
|
|
2019
Q4 | $1.23M | Buy |
+19,088
| New | +$1.09M | 0.05% | 329 |
|
|
2018
Q4 | – | Sell |
-859
| Closed | -$46.2K | – | 1787 |
|
|
2018
Q3 | $53K | Sell |
859
-10,020
| -92% | -$595K | ﹤0.01% | 1125 |
|
|
2018
Q2 | $602K | Sell |
10,879
-5,723
| -34% | -$309K | 0.04% | 478 |
|
|
2018
Q1 | $1.05M | Sell |
16,602
-842
| -5% | -$54.2K | 0.08% | 271 |
|
|
2017
Q4 | $1.07M | Sell |
17,444
-4,541
| -21% | -$284K | 0.09% | 245 |
|
|
2017
Q3 | $1.4M | Buy |
21,985
+11,073
| +101% | +$647K | 0.13% | 175 |
|
|
2017
Q2 | $608K | Buy |
10,912
+4,868
| +81% | +$265K | 0.06% | 300 |
|
|
2017
Q1 | $329K | Sell |
6,044
-4,978
| -45% | -$273K | 0.03% | 410 |
|
|
2016
Q4 | $644K | Buy |
11,022
+6,247
| +131% | +$342K | 0.08% | 276 |
|
|
2016
Q3 | $257K | Sell |
4,775
-2,276
| -32% | -$146K | 0.03% | 484 |
|
|
2016
Q2 | $519K | Buy |
7,051
+1,794
| +34% | +$127K | 0.07% | 279 |
|
|
2016
Q1 | $336K | Sell |
5,257
-1,570
| -23% | -$99K | 0.05% | 380 |
|
|
2015
Q4 | $470K | Sell |
6,827
-1,125
| -14% | -$74.3K | 0.07% | 289 |
|
|
2015
Q3 | $471K | Sell |
7,952
-1,520
| -16% | -$96.4K | 0.07% | 297 |
|
|
2015
Q2 | $630K | Sell |
9,472
-600
| -6% | -$39.5K | 0.09% | 260 |
|
|
2015
Q1 | $650K | Buy |
10,072
+9,472
| +1,579% | +$593K | 0.09% | 265 |
|
|
2014
Q4 | $35K | Buy |
+600
| New | +$33.8K | 0.01% | 1527 |
|
|
2014
Q2 | – | Sell |
-8,205
| Closed | -$426K | – | 1917 |
|
|
2014
Q1 | $426K | Buy |
+8,205
| New | +$437K | 0.06% | 469 |
|
|
2013
Q4 | – | Sell |
-910
| Closed | -$42K | – | 1627 |
|
|
2013
Q3 | $42K | Buy |
+910
| New | +$39.9K | 0.01% | 955 |
|
Other funds holding BMY
VCM
VPM
Prelude Capital Management's BMY Position: Q1 2026 in Review
Prelude Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 18% in Q1 2026, selling an estimated $183K and leaving 14,578 shares worth $884K. The position accounts for 0.07% of the portfolio, ranked #336.
Prelude Capital Management first reported a position in BMY in Q3 2013 and has held it in 31 quarters since. The position peaked at $2.75M in Q1 2021. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Prelude Capital Management held 14,578 shares of Bristol-Myers Squibb worth $884K as of Q1 2026.
- Prelude Capital Management sold 3,141 Bristol-Myers Squibb shares in Q1 2026, an estimated $183K.
- Bristol-Myers Squibb made up 0.07% of Prelude Capital Management's portfolio in Q1 2026, its #336 holding.
- Prelude Capital Management first reported a position in Bristol-Myers Squibb in Q3 2013 and has held it in 31 quarters since.
- Prelude Capital Management's Bristol-Myers Squibb position peaked at $2.75M in Q1 2021.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.